WHO Drug Information Vol. 20, No. 1, 2006 - World Health ...

More documents

Recommendations

Info

WHO Drug Information, Vol. 20, No. 1, 2006 Recommended INN: List 55C 35H 36N 4O 6PdH 3 CH 3 CHCH 3CO 2 HONPdNHHOH 3 CHHNCH 3NCH 3O CH 3Opagibaximabumpagibaximabpagibaximabpagibaximabimmunoglobulin G1, anti-(Staphylococcus epidermidis lipoteichoicacid)(human-mouse monoclonal heavy chain), disulfide with humanmousemonoclonal κ-chain, dimerimmunoglobuline G1, anti-(acide lipotéichoïque Staphylococcusepidermis), dimère du disulfure entre la chaîne lourde et la chaîne κde l’anticorps monoclonal chimérique homme-sourisinmunoglobulina G1, anti-(ácido lipoteicoico de Staphylococcusepidermis), dímero del disulfuro entre la cadena pesada y la cadenaκ del anticuerpo monoclonal quimérico hombre-ratónC 6462H 9996N 1728O 2028S 54palirodenumpalirodenpalirodènepalirodeno1-[2-(biphenyl-4-yl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine1-[2-(biphényl-4-yl)éthyl]-4-[3-(trifluorométhyl)phényl]-1,2,3,6-tétrahydropyridine1-[2-(bifenil-4-il)etil]-4-[3-(trifluorometil)fenil]-1,2,3,6-tetrahidropiridinaC 26H 24F 3NNCF 3peforelinumpeforelinpéforélinepeforelina5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-histidyl-L-α−asparagyl-L-tryptophyl-L-lysyl-L-prolylglycinamide5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-séryl-L-histidyl-L-α-aspartyl-L-tryptophyl-L-lysyl-L-prolylglycinamide5-oxo-L-prolil-L-histidil-L-triptofil-L-seril-L-histidil-L-α-asparagil-L-triptofil-L-lisil-L-prolilglicinamida47
Recommended INN: List 55 WHO Drug Information, Vol. 20, No. 1, 2006C 59H 74N 18O 14ONHHOHis Trp Ser His Asp Trp Lys ProGly NH 2plerixaforumplerixaforplérixaforplerixafor1,1'-(1,4-phenylenebismethylene)bis(1,4,8,11-tetraazacyclotetradecane)1,1'-(1,4-phénylènebisméthylène)bis(1,4,8,11-tétraazacyclotétradécane)1,1'-(1,4-fenilenobismetileno)bis(1,4,8,11-tetraazaciclotetradecano)C 28H 54N 8HNNHHNNNNHHNNHplitidepsinumplitidepsinplitidepsineplitidepsina3,6-anhydro(N-{(2S,4S)-4-[(3S,4R,5S)-3-hydroxy-4-{[N-(2-oxopropanoyl)-L-prolyl-N-methyl-D-leucyl-L-threonyl]amino}-5-methylheptanoyloxy]-2,5-dimethyl-3-oxohexanoyl}-L-leucyl-L-prolyl-N,O-dimethyl-L-tyrosine)(-)-(3S,6R,7S,10R,11S,15S,17S,20S,25aS)-11-hydroxy-3-(4-méthoxybenzyl)-2,6,17-triméthyl-15-(1-méthyléthyl)-7-[[(2R)-4-méthyl-2-[méthyl[[(2S)-1-(2-oxopropanoyl)pyrrolidin-2-yl]carbonyl]amino]pentanoyl]amino]-10-[(1S)-1-méthylpropyl]-20-(2-méthylpropyl)tétradécahydro-15H-pyrrolo[2,1-f]=[1,15,4,7,10,20]dioxatétrazacyclotricosine-1,4,8,13,16,18,21(17H)-heptone3,6-anhidro(N-{(2S,4S)-4-[(3S,4R,5S)-3-hidroxi-4-{[N-(2-oxopropanoil)-L-prolil-N-metil-D-leucil-L-treonil]amino}-5-metilheptanoiloxi]-2,5-dimetil-3-oxohexanoil}-L-leucil-L-prolil-N,O-dimetil-L-tirosina)48
Page 1 and 2: WHODRUGINFORMATIONV O L U M E 20•
Page 3 and 4: World Health OrganizationWHO Drug I
Page 5 and 6: Counterfeit MedicinesWHO Drug Infor
Page 7 and 8: Biological MedicinesWHO Drug Inform
Page 9 and 10: Biological MedicinesWHO Drug Inform
Page 11 and 12: Safety and Efficacy IssuesWHO Drug
Page 21 and 22: Access to MedicinesWHO Drug Informa
Page 27 and 28: WHO Drug Information Vol 20, No. 1,
Page 29 and 30: Regulatory Action and NewsWHO Drug
Page 31 and 32: Recent Publications, Information an
Page 33 and 34: Recent Publications, Information an
Page 35 and 36: General InformationWHO Drug Informa
Page 37 and 38: General InformationWHO Drug Informa
Page 39 and 40: Recommended INN: List 55 WHO Drug I
Page 47: Recommended INN: List 55 WHO Drug I
Page 59: Recommended INN: List 55 WHO Drug I

WHO Drug Information Vol. 20, No. 1, 2006 - World Health ...

Create successful ePaper yourself

Delete template?

Save as template?